Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide.
Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of …

Epilepsy is a common neurological disorder that affects over 70 million people worldwide.
Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients …

Epilepsy is common in patients with brain tumours and can substantially affect daily life,
even if the tumour is under control. Several factors affect the mechanism of seizures in brain …

The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from
potentially harmful endogenous and exogenous substances. BBB active drug efflux …

The blood–brain barrier (BBB) serves as a protective mechanism for the brain by preventing
entry of potentially harmful substances from free access to the central nervous system …

Drug‐resistant epilepsy with uncontrolled severe seizures despite state‐of‐the‐art medical
treatment continues to be a major clinical problem for up to one in three patients with …

In the last 30 years, over 20 new anti-seizure medicines (ASMs) have been introduced into
the market for the treatment of epilepsy using well-established preclinical seizure and …

Epilepsy is the most common serious chronic neurological disorder. Current data show that
one-third of patients do not respond to anti-epileptic drugs (AEDs). Most non-responsive …

Animal seizure and epilepsy models continue to play an important role in the early discovery
of new therapies for the symptomatic treatment of epilepsy. Since 1937, with the discovery of …

Medical intractability, ie the absence of any response to anti-epileptic drug (AED) therapy, is
an unresolved problem in many patients with epilepsy. Mechanisms of intractability are not …